Weekly Recap | NMTC.US -12.81%, consensus target well above spotWeekly Review·2 days ago, 01:06 AMNMTC-5.08%
NeuroOne Medical Technologies shares are trading higher after the company announced it has completed three separate large-animal procedures using its next-generation StereoCED platform.benzinga_article·Aug 27 at 09:03 AMNMTC-5.08%
NeuroOne reports successful large-animal procedures using next-generation StereoCED platformPUBT·Aug 27 at 08:06 AMNMTC-5.08%
Analyst Justin Walsh Reiterates Buy on NeuroOne, Maintains $8 Target on Partner-Driven RF Ablation Growth and Pipeline UpsideTip Ranks·Aug 18 at 01:47 PMNMTC-5.08%
Niche Tech and Specialized Equities Show Divergent Mid-2026 MetricsGlobal Report·Aug 18 at 04:43 AMABEV+0.52%NMTC-5.08%
Anthony Vendetti Maintains Buy on NeuroOne, Reaffirms $5 Price Target on Growing Product Momentum and Diversified Neuro Ablation PipelineTip Ranks·Aug 15 at 06:45 AMNMTC-5.08%
NeuroOne (NMTC) Fiscal Q3 2026 Earnings Call: Orders Rise 43%, Margin Reaches 59.9%TradingKey·Aug 14 at 03:32 AMNMTC-5.08%
NMTC: Q3 FY2026 delivered 16% revenue growth, 59.9% gross margin, and key milestones for global expansionQuartr·Aug 13 at 08:39 AMNMTC-5.08%
NeuroOne Fiscal Q3 2026 Earnings: Gross Margin Expands as Net Loss WidensTradingKey·Aug 13 at 07:12 AMNMTC-5.08%
NeuroOne Medical Market Development Director Mark Christianson sells 10,000 shares for $31,773PUBT·Jul 2 at 03:41 PMNMTC-5.08%
